Chester County News and Community Website
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), headquartered in West Chester, PA, is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. For more information, visit www.verrica.com.
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that its President and CEO, Jayson Rieger, PhD, MBA, will participate in a fireside chat at the TD Cowen 45th …
Verrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled encouraging clinical data for its investigational therapy, VP-315, at the 2025 Winter Clinical Dermatology Conference in Miami, Florida. The Phase 2 …
Verrica Showcases Promising VP-315 Data at Dermatology Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has provided an update on the commercial strategy for its flagship product YCANTH, a treatment for molluscum contagiosum. The company reported strong …
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced a significant stock option grant to David Zawitz, the company’s newly appointed Chief Operating Officer. The Compensation Committee approved a …
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that its partner, Torii Pharmaceutical Co. Ltd., has submitted a New Drug Application (NDA) in Japan for TO-208, a cantharidin-based …
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) released its third-quarter financial results for 2024, unveiling a strategic restructuring plan to reduce expenses and improve market access for its …
Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced a strategic restructuring aimed at reducing costs and broadening the reach of YCANTH®, its treatment for molluscum contagiosum.
Verrica Pharmaceuticals Streamlines Operations to Enhance YCANTH Access Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that Ted White, its President and CEO, will be taking part in a fireside chat at the H.C. Wainwright 26th …
Verrica Pharmaceuticals CEO to Present at Global Investment Conference Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced its financial results this week for the second quarter ended June 30, 2024, reporting net revenue of $4.9 million for …
Verrica Pharmaceuticals Reports Steady Growth with Q2 Financial Results Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week that Part 2 of its Phase 2 clinical trial for VP-315, a potential first-in-class oncolytic peptide, has yielded …
Verrica Pharmaceuticals Reports Promising Phase 2 Results for VP-315 in Basal Cell Carcinoma Read More